FRM
DAWN

Fox Run Management’s Day One Biopharmaceuticals DAWN Stock Holding History

Fox Run Management’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-33,639
Closed -$314K – 958
2025
Q4 		$314K Buy
33,639
+7,707
+30% +$64.4K 0.05% 684
2025
Q3 		$183K Buy
+25,932
New +$178K 0.03% 821

Other funds holding DAWN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
KC
Kryger Capital London, United Kingdom $1.41B AUM 86.31% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

Fox Run Management's DAWN Position: Q1 2026 in Review

Fox Run Management sold out of Day One Biopharmaceuticals (DAWN) in Q1 2026, closing a stake of 33,639 shares — an estimated $314K sold.

Fox Run Management first reported a position in DAWN in Q3 2025 and held it in 2 quarters. The position peaked at $314K in Q4 2025. 206 funds tracked by Wall St. Rank hold DAWN as of Q1 2026.

  • Fox Run Management reported no remaining Day One Biopharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Fox Run Management sold 33,639 Day One Biopharmaceuticals shares in Q1 2026, an estimated $314K.
  • Fox Run Management first reported a position in Day One Biopharmaceuticals in Q3 2025 and held it in 2 quarters.
  • Fox Run Management's Day One Biopharmaceuticals position peaked at $314K in Q4 2025.
  • 206 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q1 2026.

Based on Fox Run Management's 13F filing for Q1 2026, filed 12 May 2026.